Biomarkers for antibody-drug conjugate monotherapy or combination therapy
CN110352201A
The subcutaneous administration of antibody drug conjugate for cancer therapy
EP3600283A1
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
CN110392580A
With topoisomerase-I inhibiting antibody-drug conjugate (ADC) treatment Small Cell Lung Cancer (SCLC) of targeting TROP-2
US2018185351A1
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CN110248680A
The therapy for metastatic bladder transitional cell carcinoma of health (IMMU-132) is replaced using the husky western trastuzumab dagger-axe dimension of antibody-drug conjugates
US2018110772A1
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US2018051085A1
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
WO2018217227A1
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
WO2018053080A1
Anti-histone therapy in acute kidney injury
US2018057574A1
Anti-histone therapy in acute kidney injury
US2017360770A1
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
CN109562172A
The effect of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancer
US2017281791A1
Anti-trop-2 antibody-drug conjugates and uses thereof
CN109310385A
Anti- TROP-2-SN-38 antibody drug conjugate is used for the effect of checkpoint inhibitor recurrence/refractory tumors therapy
US2017216447A1
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
WO2017180565A1
Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers
US2017209594A1
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US2017224837A1
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
